


PHARMACEUTICAL 2022



Timber Pharmaceuticals Inc. Rank 340 of 475





PHARMACEUTICAL 2022



Timber Pharmaceuticals Inc. Rank 340 of 475

The relative strengths and weaknesses of Timber Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Timber Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Timber Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is -254%, being 23% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	17,119
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,192
Liabilities, Non-Current	405
Other Assets	766
Other Compr. Net Income	0
Other Expenses	-30
Other Liabilities	38
Other Net Income	-19
Property and Equipment	16
Research and Development	6,150
Revenues	887
Selling, General and Administrative Expense	5,387

Output Variable	Value in 1000 USD
Assets	17,901
Liabilities	4,635
Expenses	11,507
Stockholders Equity	13,267
Net Income	-10,639
Comprehensive Net Income	-10,639
Economic Capital Ratio	-254%